<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893239</url>
  </required_header>
  <id_info>
    <org_study_id>CDI01</org_study_id>
    <nct_id>NCT04893239</nct_id>
  </id_info>
  <brief_title>Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies</brief_title>
  <official_title>Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumen Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumen Bioscience, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201&#xD;
      components via enteric capsules in the gut of individuals with ostomies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of capsules and/or transit markers in ostomy fluid by visual observation</measure>
    <time_frame>Up to 12 hours after dose</time_frame>
    <description>Presence or absence of capsules and/or transit markers in ostomy fluid by visual observation</description>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>C. Diff. Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LMN-201</intervention_name>
    <description>Components of LMN-201</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the clinical trial&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Stable ostomy (no revisions in the last 6 months)&#xD;
&#xD;
          -  At least 19 years old&#xD;
&#xD;
          -  Medically stable, but may be on medications for chronic conditions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to provide adequate informed consent&#xD;
&#xD;
          -  Non-English speakers&#xD;
&#xD;
          -  Clinically significant disease&#xD;
&#xD;
          -  Women who are pregnant, intending to become pregnant, or breastfeeding&#xD;
&#xD;
          -  Use of anti-diarrheal medicine&#xD;
&#xD;
          -  Suffer gastroparesis&#xD;
&#xD;
          -  Opioid use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brian Finrow, JD</last_name>
    <phone>206-899-1904</phone>
    <email>trials@lumen.bio</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carl Mason, MD</last_name>
    <phone>206-899-1904</phone>
    <email>trials@lumen.bio</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Coral Sea Clinical Research Institute</name>
      <address>
        <city>North Mackay</city>
        <state>Queensland</state>
        <zip>4740</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Gibson</last_name>
      <phone>+61 7 4910 9532</phone>
      <email>trialnurse@coralseaclinical.com</email>
    </contact>
    <investigator>
      <last_name>James Daveson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

